专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO2003073910A2 ASSAYS FOR CANCER PATIENT MONITORING BASED ON LEVELS OF ANALYTE COMPONENTS OF THE PLASMINOGEN ACTIVATOR SYSTEM IN BODY FLUID SAMPLES 审中-公开
标题翻译：基于体液激素系统分析物组分在体液样本中的癌症患者监测分析
公开(公告)号：WO2003073910A2
公开(公告)日：2003-09-12
申请号：PCT/US2003/005957
申请日：2003-02-27
申请人： BAYER CORPORATION
发明人： CARNEY, Walter, P. , HAMER, Peter, J.
IPC分类号： A61B
CPC分类号： G01N33/57484 , G01N33/86 , G01N2333/8132 , G01N2333/9723 , G01N2800/52 , Y10T436/25
摘要： The present invention describes clinically and medically important methods of examining, screening over time, and monitoring the outcome of a cancer patient who is undergoing treatment or therapy for his or her disease. More specifically, the invention provides a method of monitoring the progression of disease, or the effectiveness of cancer treatment, in a cancer patient by measuring the levels of one or more analytes of the plasminogen activator (uPA) system, namely, uPA, PAI-1 and the complex of uPA:PAI-1, in a sample taken from the cancer patient, preferably, before treatment, at the start of treatment, and at various time intervals during treatment. As a result of performing the method, an increase or elevation in the levels of one or more of the PA system analytes in the cancer patient compared with the levels one or more of the respective PA system analytes in normal control individuals serves as an indicator of cancer advancement or progression and/or a lack of treatment effectiveness for the patient.
摘要翻译：本发明描述了临床和医学上重要的检查，随时间筛选和监测正在接受他或她的疾病的治疗或治疗的癌症患者的结果的重要方法。更具体地说，本发明提供了通过测量纤溶酶原激活剂（uPA）系统的一种或多种分析物（即uPA，PAI-1）的水平来监测癌症患者的疾病进展或癌症治疗的有效性的方法， 1和uPA：PAI-1的复合物在取自癌症患者的样品中，优选在治疗之前，在治疗开始时以及在治疗期间的不同时间间隔进行。作为实施该方法的结果，与正常对照个体中的一种或多种相应PA系统分析物的水平相比，癌症患者中的一种或多种PA系统分析物的水平的升高或升高用作癌症进展或进展和/或对患者缺乏治疗效果。

2. 发明申请

WO2003073909A2 ASSAYS FOR CANCER PATIENT MONITORING BASED ON LEVELS OF EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) EXTRACELLULAR DOMAIN (ECD) ANALYTE, ALONE OR IN COMBINATION WITH OTHER ANALYTES, IN BODY FLUID SAMPLES 审中-公开
标题翻译：基于水平生长因子受体（EGFR）细胞外区域（ECD）分析，或与其他分析物组合在体液样品中进行癌症患者监测的测定
公开(公告)号：WO2003073909A2
公开(公告)日：2003-09-12
申请号：PCT/US2003/005831
申请日：2003-02-27
申请人： BAYER CORPORATION
发明人： CARNEY, Walter, P. , HAMER, Peter, J. , LIPTON, Allan , LEITZEL, Kim , ALI, Suhail, M.
IPC分类号： A61B
CPC分类号： G01N33/57488 , G01N33/57407 , G01N33/57415 , G01N33/57419 , G01N33/57423 , G01N33/57434 , G01N33/57449 , G01N2333/485 , G01N2333/71 , G01N2800/52
摘要： The present invention describes clinically and medically important methods of monitoring outcome of a cancer patient who is suffering from disease or who is undergoing treatment or therapy for his or her disease. More specifically, the invention provides a method of monitoring the progression of disease or cancer treatment effectiveness in a cancer patient by measuring the level of the extracellular domain (ECD) of the epidermal growth factor receptor (EGFR) in a sample taken from the cancer patient, preferably, before treatment, at the start of treatment, and at various time intervals during treatment, wherein a decrease in the level of the ECD of the EGFR in the cancer patient compared with the level of the ECD of the EGFR in normal control individuals serves as an indicator of cancer advancement or progression and/or a lack of treatment effectiveness for the patient. As another aspect of determining disease outcome and survival, the invention further provides assessing both EGFR and HER-2/neu levels, in combination, in a patient sample. A finding of decreased levels of EGFR concomitantly with elevated or increased levels of HER-2/neu relative to control levels indicates poor outcome and short time to progression.
摘要翻译：本发明描述了临床和医学上重要的监测患有疾病或正在接受治疗或治疗他或她的疾病的癌症患者的结果的方法。更具体地，本发明提供了通过测量取自癌症患者的样品中表皮生长因子受体（EGFR）的细胞外结构域（ECD）的水平来监测癌症患者的疾病进展或癌症治疗有效性的方法，优选在治疗前，治疗开始时和治疗期间的不同时间间隔，其中与正常对照个体中EGFR的ECD水平相比，癌症患者中EGFR的ECD水平降低作为癌症进展或进展的指标和/或患者缺乏治疗有效性。作为确定疾病结果和存活的另一方面，本发明进一步提供了在患者样品中组合评价EGFR和HER-2 / neu水平。与控制水平相比，伴随HER-2 / neu水平升高或升高的EGFR水平降低的发现表明结果差，进展时间短。

3. 发明申请

WO2003073909A3 ASSAYS TO MONITOR LEVELS OF EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) EXTRACELLULAR DOMAIN (ECD) IN CANCER PATIENTS 审中-公开
公开(公告)号：WO2003073909A3
公开(公告)日：2003-09-12
申请号：PCT/US2003/005831
申请日：2003-02-27
申请人： BAYER CORPORATION
发明人： CARNEY, Walter, P. , HAMER, Peter, J. , LIPTON, Allan , LEITZEL, Kim , ALI, Suhail, M.
IPC分类号： G01N33/48
摘要： The present invention describes clinically and medically important methods of monitoring outcome of a cancer patient who is suffering from disease or who is undergoing treatment or therapy for his or her disease. More specifically, the invention provides a method of monitoring the progression of disease or cancer treatment effectiveness in a cancer patient by measuring the level of the extracellular domain (ECD) of the epidermal growth factor receptor (EGFR) in a sample taken from the cancer patient, preferably, before treatment, at the start of treatment, and at various time intervals during treatment, wherein a decrease in the level of the ECD of the EGFR in the cancer patient compared with the level of the ECD of the EGFR in normal control individuals serves as an indicator of cancer advancement or progression and/or a lack of treatment effectiveness for the patient. As another aspect of determining disease outcome and survival, the invention further provides assessing both EGFR and HER-2/neu levels, in combination, in a patient sample. A finding of decreased levels of EGFR concomitantly with elevated or increased levels of HER-2/neu relative to control levels indicates poor outcome and short time to progression.

4. 发明公开

EP1489968A2 ASSAYS FOR CANCER PATIENT MONITORING BASED ON LEVELS OF ANALYTE COMPONENTS OF THE PLASMINOGEN ACTIVATOR SYSTEM IN BODY FLUID SAMPLES 有权
标题翻译：测定法基于所述ANALYTENKOMPONENTEN纤溶酶原激活系统的体液样品镜肿瘤病人组监测
公开(公告)号：EP1489968A2
公开(公告)日：2004-12-29
申请号：EP03711275.2
申请日：2003-02-27
申请人： BAYER CORPORATION
发明人： CARNEY, Walter, P. , HAMER, Peter, J.
IPC分类号： A61B6/00
CPC分类号： G01N33/57484 , G01N33/86 , G01N2333/8132 , G01N2333/9723 , G01N2800/52 , Y10T436/25
摘要： The present invention describes clinically and medically important methods of examining, screening over time, and monitoring the outcome of a cancer patient who is undergoing treatment or therapy for his or her disease. More specifically, the invention provides a method of monitoring the progression of disease, or the effectiveness of cancer treatment, in a cancer patient by measuring the levels of one or more analytes of the plasminogen activator (uPA) system, namely, uPA, PAI-1 and the complex of uPA:PAI-1, in a sample taken from the cancer patient, preferably, before treatment, at the start of treatment, and at various time intervals during treatment. As a result of performing the method, an increase or elevation in the levels of one or more of the PA system analytes in the cancer patient compared with the levels one or more of the respective PA system analytes in normal control individuals serves as an indicator of cancer advancement or progression and/or a lack of treatment effectiveness for the patient.

5. 发明公开

EP1573316A2 ASSAYS FOR CANCER PATIENT MONITORING BASED ON LEVELS OF EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) EXTRACELLULAR DOMAIN (ECD) ANALYTE, ALONE OR IN COMBINATION WITH OTHER ANALYTES, IN BODY FLUID SAMPLES 有权
标题翻译：测定法监测基于分析物的胞外域（ECD）与表皮生长因子受体（EGFR），单独或与其它分析物在体液样本组合镜肠癌患者
公开(公告)号：EP1573316A2
公开(公告)日：2005-09-14
申请号：EP03709354.9
申请日：2003-02-27
申请人： BAYER CORPORATION
发明人： CARNEY, Walter, P. , HAMER, Peter, J. , LIPTON, Allan , LEITZEL, Kim , ALI, Suhail, M.
IPC分类号： G01N33/48
CPC分类号： G01N33/57488 , G01N33/57407 , G01N33/57415 , G01N33/57419 , G01N33/57423 , G01N33/57434 , G01N33/57449 , G01N2333/485 , G01N2333/71 , G01N2800/52
摘要： The present invention describes clinically and medically important methods of monitoring outcome of a cancer patient who is suffering from disease or who is undergoing treatment or therapy for his or her disease. More specifically, the invention provides a method of monitoring the progression of disease or cancer treatment effectiveness in a cancer patient by measuring the level of the extracellular domain (ECD) of the epidermal growth factor receptor (EGFR) in a sample taken from the cancer patient, preferably, before treatment, at the start of treatment, and at various time intervals during treatment, wherein a decrease in the level of the ECD of the EGFR in the cancer patient compared with the level of the ECD of the EGFR in normal control individuals serves as an indicator of cancer advancement or progression and/or a lack of treatment effectiveness for the patient. As another aspect of determining disease outcome and survival, the invention further provides assessing both EGFR and HER-2/neu levels, in combination, in a patient sample. A finding of decreased levels of EGFR concomitantly with elevated or increased levels of HER-2/neu relative to control levels indicates poor outcome and short time to progression.

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式